Biological treatment for erythrodermic psoriasis

References

• Yan D, Afifi L, Jeon C, et al. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018Jul15; 24(7). PubMed PMID: 30261563. DOI:10.5070/D3247040909.
   Google Scholar
• Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. PubMed PMID: 2530253. J Am Acad Dermatol. 1989 Nov;21(5 Pt 1):985–991.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Dogra S, Bandyopadhyay MR, et al. Clinical patterns and clinicopathologic correlation of 100 patients with Erythroderma in a tertiary care institute in India. Skinmed. 2021;19(6):440–450. PubMed PMID: 35022116.
   PubMedGoogle Scholar
• Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica. 1988;176(4):182–190. PubMed PMID: 2967779.
   PubMedGoogle Scholar
• Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000Sep;14(5):382–388. PubMed PMID: 11305380.
   PubMed Web of Science ®Google Scholar
• Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology. 1993;187(Suppl 1):30–37. PubMed PMID: 8369577.
   Google Scholar
• Megna M, Ruggiero A, Marasca C, et al. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020Jun;314:328–329. PubMed PMID: 32301363.
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022Mar10;11(6):1511. PubMed PMID: 35329838; PubMed Central PMCID: PMCPMC8950226.
   PubMed Web of Science ®Google Scholar
• Lo Y, Chiu HY, Tsai TF. Clinical features and genetic polymorphism in Chinese patients with erythrodermic psoriasis in a single dermatologic clinic. Mol Diagn Ther. 2020Feb;24(1):85–93. PubMed PMID: 31820331.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009Jul30;361(5):496–509. PubMed PMID: 19641206.
   PubMed Web of Science ®Google Scholar
• Li LF, Sujan SA, Yang H, et al. Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol. 2005Mar;30 2:125–127. PubMed PMID: 15725235.
   PubMed Web of Science ®Google Scholar
• Kasumagic-Halilovic E. Total serum immunoglobulin E levels in patients with psoriasis. Mater Socio Med. 2020 Jun;32(2):105–107. doi: PubMed PMID: 32843856; PubMed Central PMCID: PMCPMC7428889.
   PubMedGoogle Scholar
• Zhang P, Chen HX, Duan YQ, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technolog Med Sci. 2014Aug;344:596–601. PubMed PMID: 25135734.
   PubMedGoogle Scholar
• Deeva I, Mariani S, De Luca C, et al. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine. 2010Feb;492:163–170. PubMed PMID: 19879157.
   PubMed Web of Science ®Google Scholar
• Senra L, Mylonas A, Kavanagh RD, et al. IL-17E (IL-25) Enhances innate immune responses during skin inflammation. J Invest Dermatol. 2019Aug;1398:1732–1742.e17. PubMed PMID: 30738055.
   PubMed Web of Science ®Google Scholar
• Irie K, Yamamoto T. Serum levels and expression of IL-25 in patients with psoriatic erythroderma. Australas J Dermatol. 2022 2022 May 04; 63(3): n/a(n/a). DOI:10.1111/ajd.13855.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang S, Li L, et al. Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis. Cytokine. 2021 Feb;138:155391. PubMed PMID: 33302223.
   PubMed Web of Science ®Google Scholar
• Di Martino L, Osme A, Kossak-Gupta S, et al. TWEAK/Fn14 is overexpressed in Crohn’s disease and mediates experimental ileitis by regulating critical innate and adaptive immune pathways. Cell Mol Gastroenterol Hepatol. 2019;8(3):427–446.
   PubMed Web of Science ®Google Scholar
• Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive Immunity. Cell. 2005;123(5):931–944.
   PubMed Web of Science ®Google Scholar
• Wang W, Yu X, Wu C, et al. IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis. Int J Med Sci. 2017;14(10):1002–1007. PubMed PMID: 28924372; PubMed Central PMCID: PMCPMC5599924.
   PubMed Web of Science ®Google Scholar
• Tomasini C, Aloi F, Solaroli C, et al. Psoriatic erythroderma: a histopathologic study of forty-five patients. Dermatology. 1997;194(2):102–106. PubMed PMID: 9094455.
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006Jul;1551:156–159. PubMed PMID: 16792768.
   PubMed Web of Science ®Google Scholar
• Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. PubMed PMID: 22413927, Br J Dermatol. 2012 Aug;167(2):417–423.
   PubMed Web of Science ®Google Scholar
• Fraga NA, Paim Mde F, Follador I, et al. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol. 2011Jul-Aug;864 Suppl 1:S144–7. PubMed PMID: 22068796; eng.
   PubMed Web of Science ®Google Scholar
• Talat H, Wahid Z, Feroz F, et al. Erythrodermic psoriasis and hepatitis C infection treated with pegylated interferon and anti-TNFα α(Etanercept) therapy. J Coll Physicians Surg Pak. 2017Sep; 279: S77–s79. PubMed PMID: 28969730; 264
   PubMed Web of Science ®Google Scholar
• Romero-Maté A, García-Donoso C, Martinez-Morán C, et al. Long-term management of erythrodermic psoriasis with anti-TNF agents. Dermatol Online J. 2010Jun15; 16(6):15. PubMed PMID: 20579470.
   PubMedGoogle Scholar
• Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. PubMed PMID: 19665821, J Am Acad Dermatol. 2010 Apr;62(4):655–662.
   PubMed Web of Science ®Google Scholar
• Torii H, Terui T, Matsukawa M, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016Jul;437:767–778. PubMed PMID: 26704926.
   PubMed Web of Science ®Google Scholar
• Takahashi MD, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007Oct;157(4):828–831. PubMed PMID: 17711530.
   PubMed Web of Science ®Google Scholar
• Heikkilä H, Ranki A, Cajanus S, et al. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005Dec;14112:1607–1610. PubMed PMID: 16365275.
   PubMedGoogle Scholar
• Buggiani G, D’Erme AM, Krysenka A, et al. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatol Ther. 2012May-Jun;253:283–285. PubMed PMID: 22913449.
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007Feb;1562:329–336. PubMed PMID: 17223874.
   PubMed Web of Science ®Google Scholar
• Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010Apr;1624:780–785. PubMed PMID: 19863499.
   PubMed Web of Science ®Google Scholar
• Xia P, Li YH, Liu Z, et al. Recalcitrant paradoxical pustular psoriasis induced by infliximab: two case reports. World J Clin Cases. 2021May26;9(15):3655–3661. PubMed PMID: 34046466; PubMed Central PMCID: PMCPMC8130067.
   PubMed Web of Science ®Google Scholar
• Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with Adalimumab. Dermatol Ther. 2009Nov22;22(Suppl 1):S16–8. PubMed PMID: 19891686.
   PubMedGoogle Scholar
• Nowsheen S, Kohorst JJ, El-Azhary RA. Adalimumab-induced erythrodermic reactions. Int J Dermatol. 2019Oct;58(10):e204–e206. PubMed PMID: 31135963.
   PubMed Web of Science ®Google Scholar
• Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following Adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab. Postepy Dermatol Alergol. 2019Aug;36(4):495–497. PubMed PMID: 31616228; PubMed Central PMCID: PMCPMC6791146 Novartis, Eli Lilly, Celgene.
   PubMed Web of Science ®Google Scholar
• Lee WK, Kim GW, Cho HH, et al. Erythrodermic Psoriasis treated with Golimumab: a case report. Ann Dermatol. 2015Aug;274:446–449. PubMed PMID: 26273164; PubMed Central PMCID: PMCPMC4530158.
   PubMed Web of Science ®Google Scholar
• Kudsi M, Alzabibi MA, Shibani M. Two cases of Erythrodermic psoriasis treated with Golimumab. Ann Med Surg. 2022Jun; 78: 103961. PubMed PMID: 35734731; PubMed Central PMCID: PMCPMC9207129.
   PubMed Web of Science ®Google Scholar
• Mateo S, García-Martínez FJ, Sánchez-Aguilar D, et al. Psoriasiform exfoliative erythroderma induced by golimumab. Clin Exp Dermatol. 2014Oct;397:813–815. PubMed PMID: 25156341.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Umezawa Y, Sakurai S, et al. Efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic Psoriasis: 52-week results. Dermatol Ther (Heidelb). 2022Jun;126:1397–1415. PubMed PMID: 35622315; PubMed Central PMCID: PMCPMC9209588.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, et al. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017Sep;319:e420–e421. PubMed PMID: 28319281.
   PubMed Web of Science ®Google Scholar
• Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, et al. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018Jul;314:e12607. PubMed PMID: 29663615.
   PubMed Web of Science ®Google Scholar
• Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018Jun;178(6):1439–1440. PubMed PMID: 29265175.
   PubMed Web of Science ®Google Scholar
• Panda M, Raj C, Panda AK, et al. Secukinumab in erythrodermic psoriasis: real world experience of 6 patients successfully treated by injecting at unconventional sites. Indian J Dermatol. 2021Nov-Dec;666:677–680. PubMed PMID: 35283534.
   PubMed Web of Science ®Google Scholar
• Dogra S, Bishnoi A, Narang T, et al. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018Jul;314:e12611. PubMed PMID: 29687662.
   PubMed Web of Science ®Google Scholar
• Pizzatti L, Mugheddu C, Sanna S, et al. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020May;333:e13348. PubMed PMID: 32239791.
   PubMed Web of Science ®Google Scholar
• Lu J, Tang S, Yu N, et al. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report. J Int Med Res. 2020Nov;4811:300060520969494. PubMed PMID: 33161790; PubMed Central PMCID: PMCPMC7658516.
   PubMed Web of Science ®Google Scholar
• Polat Ekinci A, Bölük KN, Babuna Kobaner G. Secukinumab and Acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: a case series of high efficacy and safety profile. Dermatol Ther. 2021Jan;34(1):e14704. PubMed PMID: 33368934.
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8(6):770. PubMed PMID: 31159169.
   PubMed Web of Science ®Google Scholar
• Morita A, Okubo Y, Morisaki Y, et al. Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. Dermatol Ther (Heidelb). 2022Feb;122:481–494. PubMed PMID: 34967916; PubMed Central PMCID: PMCPMC8717693.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. PubMed PMID: 27726163.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019Feb;332:325–332. PubMed PMID: 30317671; PubMed Central PMCID: PMCPMC6587497.
   PubMed Web of Science ®Google Scholar
• Lo Y, Tsai TF. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series. PubMed PMID: 31145806, Br J Dermatol. 2019 Nov;181(5):1106–1107.
   PubMed Web of Science ®Google Scholar
• Lo Y, Huang Y-H, Tsai T-F. Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: a bicentric retrospective study [CORRESPONDENCE]. Dermatol Sin. 2021 April 1;39(2):87–88.
   Web of Science ®Google Scholar
• Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022; 07/01;36(7):e574–e576. DOI:10.1111/jdv.18069
   PubMed Web of Science ®Google Scholar
• Pangilinan MCG, Sermswan P, Asawanonda P. Use of Anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis. Case Rep Dermatol. 2020;12(2):132–137. PubMed PMID: 32999648.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017Mar;1763:741–751. PubMed PMID: 27106510.
   PubMed Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Ferrillo M, et al. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: report of two cases. Dermatol Ther. 2020Nov;336:e14351. PubMed PMID: 32981222.
   PubMed Web of Science ®Google Scholar
• Bernardini N, Skroza N, Tolino E, et al. Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab. Dermatol Ther. 2020Nov;336:e14338. PubMed PMID: 32975343.
   PubMed Web of Science ®Google Scholar
• Masson Regnault M, Konstantinou MP, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017Sep;319:1491–1496. PubMed PMID: 28585707.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012Feb;1322:304–314. PubMed PMID: 22011907.
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015May;782:149–151. PubMed PMID: 25681953.
   PubMed Web of Science ®Google Scholar
• Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011Nov;38(11):1096–1099. PubMed PMID: 21545503.
   PubMed Web of Science ®Google Scholar
• Koutsoukou XA, Papadavid E, Theodoropoulos K, et al. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission. Dermatol Ther. 2014Sep-Oct;275:257–259. PubMed PMID: 24813816.
   PubMed Web of Science ®Google Scholar
• Santos-Juanes J, Coto-Segura P, Mas-Vidal A, et al. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010May;1625:1144–1146. PubMed PMID: 20222926.
   PubMed Web of Science ®Google Scholar
• Castiñeiras I, Fernández-Diaz L, Juárez Y, et al. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012Aug;398:730–731. PubMed PMID: 22364316.
   PubMed Web of Science ®Google Scholar
• Stinco G, Piccirillo A, Errichetti E, et al. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol. 2014May-Jun;243:387–390. PubMed PMID: 24721883.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Talamonti M, Galluzzo M, et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5(3):254–259. PubMed PMID: 24163658; PubMed Central PMCID: PMCPMC3806693.
   PubMedGoogle Scholar
• Penso L, Dray-Spira R, Weill A, et al. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. 2021Sep1;157(9):1056–1065. PubMed PMID: 34287624; PubMed Central PMCID: PMCPMC8295892.
   PubMed Web of Science ®Google Scholar
• Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014Jul-Aug;24(4):508–509. PubMed PMID: 25120233.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim HJ, Lee S, et al. Erythrodermic psoriasis improved by ustekinumab: a report of two cases. Ann Dermatol. 2016;28(1):121–122. PubMed PMID: 26848234.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018Aug25;392(10148):650–661. PubMed PMID: 30097359.
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. PubMed PMID: 14707118.
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16(1):495–521. PubMed PMID: 9597139.
   PubMedGoogle Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. PubMed PMID: 29569397.
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, et al. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020Mar;332:e13238. PubMed PMID: 31997488.
   PubMed Web of Science ®Google Scholar
• Chiang C-Y, Tsai T-F. Treatment response of patients with Erythrodermic Psoriasis after switching to guselkumab. Dermatol Ther (Heidelb). 2021;11(1):301–306. PubMed PMID: 33400156.
   PubMed Web of Science ®Google Scholar
• Suleiman AA, Khatri A, Oberoi RK, et al. Exposure-Response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet. 2020May;595:575–589. PubMed PMID: 31667790.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit-risk profiles of treatments for moderate-to-severe Plaque Psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022Jan;121:167–184. PubMed PMID: 34862951; PubMed Central PMCID: PMCPMC8776931.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of Bimekizumab and other biologics in moderate to severe plaque Psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022Aug;128:1777–1792. PubMed PMID: 35798920; PubMed Central PMCID: PMCPMC9357587.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Gooderham M, Griffiths CEM, et al. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe Psoriasis over 1 Year: a network meta-analysis. Dermatol Ther (Heidelb). 2022Mar;123:727–740. PubMed PMID: 35195887; PubMed Central PMCID: PMCPMC8941028.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017Jul15;390(10091):276–288. PubMed PMID: 28596043.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe Psoriasis. Adv Ther. 2022May;395:2256–2269. PubMed PMID: 35316500; PubMed Central PMCID: PMCPMC9056462.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PloS one. 2019;14(8):e0220868. PubMed PMID: 31412060; PubMed Central PMCID: PMCPMC6693782 for this study; RBW is a consultant to LEO Pharma for this study; AS and EB are LEO Pharma employees. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther (Heidelb). 2021;34(5):e15030–e15030. PubMed PMID: 34137492.
   PubMed Web of Science ®Google Scholar
• Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis. 2006 Sep;78(3):178–180. PubMed PMID: 17036660.
   PubMed Web of Science ®Google Scholar
• Piccirillo F, Stinco G, Patrone P. Erythrodermic psoriasis successfully treated with efalizumab. Eur J Dermatol. 2008May-Jun;18(3):357–358. PubMed PMID: 18474483.
   PubMed Web of Science ®Google Scholar
• Kop EN, Körver JE, Van Ruysevelt D, et al. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment. J Dermatolog Treat. 2009;20(1):67–69. PubMed PMID: 18651300.
   PubMed Web of Science ®Google Scholar
• Anderson KS, Petersson S, Wong J, et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010Nov;1635:1085–1089. PubMed PMID: 20716221.
   PubMed Web of Science ®Google Scholar
• Nishizawa A, Satoh T, Yokozeki H. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab. Acta Dermatol Venereol. 2012 Jul;92(4):360–361. doi: PubMed PMID: 22565356.
   PubMed Web of Science ®Google Scholar
• Wierzbicka E, Tourani JM, Guillet G. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol. 2006Jul;155(1):213–214. PubMed PMID: 16792781.
   PubMed Web of Science ®Google Scholar
• Neyns B, Meert V, Vandenbroucke F. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis. Curr Oncol. 2008Aug;15(4):196–197. PubMed PMID: 18769609; PubMed Central PMCID: PMCPMC2528307.
   PubMed Web of Science ®Google Scholar
• Ellis AG, Flohr C, Drucker AM, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535. Br J Dermatol. 2019Feb; 180(2):282–288. PubMed PMID: 30347448.
   PubMedGoogle Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Eng J Med. 2021Jul8;385(2):142–152. PubMed PMID: 33891380.
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Eng J Med. 2021Jul8;385(2):130–141. PubMed PMID: 33891379.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021Feb6;397(10273):487–498. PubMed PMID: 33549193.
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020Nov;7911:1400–1413. PubMed PMID: 32759265; PubMed Central PMCID: PMCPMC7569391.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Weinblatt ME, Mease PJ, et al. Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology. 2018Nov1;57(11):1972–1981. PubMed PMID: 30032191.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Kimball AB, Augustin M, et al. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol. 2022Jul6; PubMed PMID: 35791755. DOI:10.1111/bjd.21743.
   Google Scholar
• Puig L, Bakulev AL, Kokhan MM, et al. Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of A 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Dermatol Ther (Heidelb). 2021;11(4):1319–1332. PubMed PMID: 34060012.
   PubMed Web of Science ®Google Scholar
• Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021Apr24;397(10284):1564–1575. PubMed PMID: 33894834.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther. 2008Aug;78:2288–2297. PubMed PMID: 18723476.
   PubMed Web of Science ®Google Scholar
• Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Exp Rev Clinical Pharmacol. 2020 May;13(5):493–503. doi: PubMed PMID: 32394765.
   PubMed Web of Science ®Google Scholar
• Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019Jun;180 6:1547–1548. PubMed PMID: 30578668.
   PubMed Web of Science ®Google Scholar
• Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019Sep;813:857–859. PubMed PMID: 31078609.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther (Heidelb). 2022;35(7):e15524.
   PubMed Web of Science ®Google Scholar
• Thatiparthi A, Martin A, Liu J, et al. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021Jul;224:425–442. PubMed PMID: 33861409; PubMed Central PMCID: PMCPMC8051287.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022 Jun;14:1–18. PubMed PMID: 35695241.
   Google Scholar